Derrick R Witcher

Derrick R Witcher

UNVERIFIED PROFILE

Are you Derrick R Witcher?   Register this Author

Register author
Derrick R Witcher

Derrick R Witcher

Publications by authors named "Derrick R Witcher"

Are you Derrick R Witcher?   Register this Author

36Publications

618Reads

43Profile Views

Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys.

Biotechnol J 2019 Mar 26;14(3):e1800007. Epub 2018 Jun 26.

Department of Biotechnology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/biot.201800007DOI Listing
March 2019

Modulation of IgG1 immunoeffector function by glycoengineering of the GDP-fucose biosynthesis pathway.

Biotechnol Bioeng 2018 03 1;115(3):705-718. Epub 2017 Dec 1.

Bioprocess Research and Development, Eli Lilly and Company, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bit.26496DOI Listing
March 2018

Role of TGF-alpha in the progression of diabetic kidney disease.

Am J Physiol Renal Physiol 2017 06 1;312(6):F951-F962. Epub 2017 Mar 1.

Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajprenal.00443.2016DOI Listing
June 2017

Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody.

Protein Sci 2016 11 9;25(11):2028-2036. Epub 2016 Sep 9.

Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, 46285.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pro.3023
Publisher Site
http://dx.doi.org/10.1002/pro.3023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079263PMC
November 2016

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.

MAbs 2015 4;7(6):1084-93. Epub 2015 Sep 4.

a Departments of Drug Disposition and Development/Commercialization, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2015.1075109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966429PMC
August 2016

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.

MAbs 2015 ;7(3):483-93

a Department of Drug Disposition Development/Commercialization; Lilly Research Laboratories; Eli Lilly and Company Corporate Center , Indianapolis , IN USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2015.1016696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622971PMC
March 2016

Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.

MAbs 2012 Mar-Apr;4(2):267-73. Epub 2012 Mar 1.

Eli Lilly Research Laboratories; Eli Lilly Corporate Center; Indianapolis, IN USA; Departments of Drug Disposition Development/Commercialization; Eli Lilly Research Laboratories; Eli Lilly Corporate Center; Indianapolis, IN USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/mabs.4.2.19364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361662PMC
February 2015

Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor.

J Inflamm Res 2014 20;7:121-31. Epub 2014 Aug 20.

Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JIR.S67751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173659PMC
September 2014

Ghrelin in obesity.

Metab Syndr Relat Disord 2006 ;4(1):37-42

Lilly Research Laboratories, ADivision of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/met.2006.4.37DOI Listing
October 2012

FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.

Drug Metab Dispos 2012 Aug 14;40(8):1545-55. Epub 2012 May 14.

Departments of Drug Disposition Development/Commercialization, Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, S. Delaware St., Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.112.045864
Publisher Site
http://dx.doi.org/10.1124/dmd.112.045864DOI Listing
August 2012

A dual-monoclonal sandwich ELISA specific for hepcidin-25.

Clin Chem 2010 Nov 16;56(11):1725-32. Epub 2010 Sep 16.

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://www.clinchem.org/cgi/doi/10.1373/clinchem.2010.151522
Publisher Site
http://dx.doi.org/10.1373/clinchem.2010.151522DOI Listing
November 2010

Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency.

Br J Haematol 2009 Mar 20;144(5):789-93. Epub 2008 Dec 20.

Department of Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2008.07535.xDOI Listing
March 2009

Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.

Mol Biol Cell 2008 Dec 8;19(12):5490-505. Epub 2008 Oct 8.

Department of Drug Disposition Development/Commercialization, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://www.molbiolcell.org/doi/10.1091/mbc.e07-02-0101
Publisher Site
http://dx.doi.org/10.1091/mbc.e07-02-0101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592658PMC
December 2008

Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors.

Transfusion 2008 Oct 24;48(10):2197-204. Epub 2008 Jul 24.

Blood Research Institute, Blood Center of Wisconsin, Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226-3548, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1537-2995.2008.01823.xDOI Listing
October 2008

Tumor-derived death receptor 6 modulates dendritic cell development.

Cancer Immunol Immunother 2008 Jun 26;57(6):777-87. Epub 2007 Oct 26.

Eli Lilly and Company, BioTherapeutic Discovery Research, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-007-0413-1DOI Listing
June 2008

Ghrelin octanoylation mediated by an orphan lipid transferase.

Proc Natl Acad Sci U S A 2008 Apr 28;105(17):6320-5. Epub 2008 Apr 28.

Integrative Biology, Eli Lilly and Company, 2001 West Main Street, Greenfield, IN 46140, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0800708105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359796PMC
April 2008

Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry.

Blood 2007 Aug 13;110(3):1048-54. Epub 2007 Apr 13.

Department of Drug Disposition Bioproducts, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2006-11-05
Publisher Site
http://dx.doi.org/10.1182/blood-2006-11-057471DOI Listing
August 2007

Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.

Drug Metab Dispos 2007 Jan 18;35(1):86-94. Epub 2006 Oct 18.

Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.106.011734DOI Listing
January 2007

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.

J Biol Chem 2007 Jan 29;282(3):1709-17. Epub 2006 Nov 29.

Department of Drug Disposition Development/Commercialization and Biotechnology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M607161200DOI Listing
January 2007

IL-1beta epitope mapping using site-directed mutagenesis and hydrogen-deuterium exchange mass spectrometry analysis.

Biochemistry 2005 Aug;44(33):11106-14

Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi0505464DOI Listing
August 2005

Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen.

J Infect Dis 2005 Feb 5;191(4):596-606. Epub 2005 Jan 5.

Medical Research Service of the Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98108-1597, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/427261DOI Listing
February 2005

Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue.

Immunology 2003 Oct;110(2):225-33

Departments of BioRTP, Infectious Disease, and Cardiovascular Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783033PMC
http://dx.doi.org/10.1046/j.1365-2567.2003.01724.xDOI Listing
October 2003

Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice.

Drug Metab Dispos 2003 Apr;31(4):502-7

Department of Drug Disposition Development/Commercialization, Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.31.4.502DOI Listing
April 2003

Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.

Biochem Pharmacol 2003 Feb;65(4):657-67

Department of Drug Disposition Development/Commercialization, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-2952(02)01612-xDOI Listing
February 2003

Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions.

Biochemistry 2002 Dec;41(49):14524-31

BioResearch Technologies and Proteins, Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi0265022DOI Listing
December 2002